Literature DB >> 23341430

Reply to "Contradictory results with high-dosage rifamycin in mice and humans".

Eric L Nuermberger, Ian M Rosenthal, Rokeya Tasneen, Charles A Peloquin, Khisimuzi E Mdluli, Petros C Karakousis, Jacques H Grosset.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23341430      PMCID： PMC3553677          DOI： 10.1128/AAC.02216-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  15 in total

1.  Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Charles A Peloquin; Andrew A Vernon; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2006-03-30       Impact factor: 21.405

Review 2.  Tuberculosis pharmacotherapy: strategies to optimize patient care.

Authors:  Carole D Mitnick; Bryan McGee; Charles A Peloquin
Journal:  Expert Opin Pharmacother       Date:  2009-02       Impact factor: 3.889

3.  Contradictory results with high-dosage rifamycin in mice and humans.

Authors:  A R M Coates; Yanmin Hu; A Jindani; D A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2013-02       Impact factor: 5.191

4.  Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Andrew A Vernon; Charles A Peloquin; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2005-09-01       Impact factor: 21.405

5.  Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide.

Authors:  Y Hu; J A Mangan; J Dhillon; K M Sole; D A Mitchison; P D Butcher; A R Coates
Journal:  J Bacteriol       Date:  2000-11       Impact factor: 3.490

6.  Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Janet C Gilliland; Colby L Wells; Elizabeth J Brooks; Lisa K Woolhiser; Veronica Gruppo; Charles A Peloquin; Ian M Orme; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2010-12-06       Impact factor: 5.191

7.  Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.

Authors:  Murad Ibrahim; Chantal Truffot-Pernot; Koen Andries; Vincent Jarlier; Nicolas Veziris
Journal:  Am J Respir Crit Care Med       Date:  2009-07-09       Impact factor: 21.405

8.  Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.

Authors:  Ramesh Jayaram; Sheshagiri Gaonkar; Parvinder Kaur; B L Suresh; B N Mahesh; R Jayashree; Vrinda Nandi; Sowmya Bharat; R K Shandil; E Kantharaj; V Balasubramanian
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

9.  Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium.

Authors:  Susan E Dorman; Stefan Goldberg; Jason E Stout; Grace Muzanyi; John L Johnson; Marc Weiner; Lorna Bozeman; Charles M Heilig; Pei-Jean Feng; Ruth Moro; Masahiro Narita; Payam Nahid; Susan Ray; Edward Bates; Betial Haile; Eric L Nuermberger; Andrew Vernon; Neil W Schluger
Journal:  J Infect Dis       Date:  2012-07-30       Impact factor: 5.226

10.  Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.

Authors:  Ian M Rosenthal; Ming Zhang; Kathy N Williams; Charles A Peloquin; Sandeep Tyagi; Andrew A Vernon; William R Bishai; Richard E Chaisson; Jacques H Grosset; Eric L Nuermberger
Journal:  PLoS Med       Date:  2007-12       Impact factor: 11.069
View more
  1 in total

1.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.